ZEOXOTCBiological Products, (No Diagnostic Substances)Fiscal year ends June 30

Zeo ScientifiX, Inc.

Financials through Q2 FY2026, quarter ended Apr 30, 2026Last filing: 10-Q on Jun 15, 2026

$0.91+0.00 (+0.15%)

Close on Oct 19, 2026

Market cap: $7.08M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Apr 30, 2026

Zeo ScientifiX reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Zeo ScientifiX's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Zeo ScientifiX's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-200 reverse split on Jan 29, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ZEOX.

Gross margin81.5% · median 37.0%

Operating margin-59.1% · median -205.2%

Net margin-55.6% · median -223.5%

Company	Revenue	Growth
LCTX	$13.08M	+19.9%
ELUT	$12.14M	-0.3%
MESO	$7.50M	-26.5%
ZEOX	$6.99M	–
DYAI	$3.80M	-8.0%
ELOX	–	–

Company

Exchange: OTC
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: June 30
Employees: 33
Auditor: Weinberg & Company P.A.
SEC CIK: 1557376

Advertisement
300 × 250